- Home
- SOPH
SOPH
SOPHiA GENETICS SA
as of 07-02-2026 3:46pm EST
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 374.1M | IPO Year: | 2021 |
| Target Price: | $7.50 | AVG Volume (30 days): | 333.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $2.83 - $6.30 | Next Earning Date: | 05-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 23.09% | Revenue Growth (next year): | 19.57% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered SOPH Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of SOPHiA GENETICS SA (SOPH)
Executive Chairman
Avg Cost/Share
$6.16
Shares
65,269
Total Value
$398,632.27
Owned After
3,601,143
Executive Chairman
Avg Cost/Share
$5.93
Shares
18,410
Total Value
$108,058.02
Owned After
3,601,143
Chief Executive Officer
Avg Cost/Share
$5.78
Shares
50,069
Total Value
$290,329.01
Owned After
3,601,143
Chief Executive Officer
Avg Cost/Share
$5.70
Shares
1,373
Total Value
$7,826.10
Owned After
3,601,143
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$5.50
Shares
5,000
Total Value
$27,524.50
Owned After
240,780
SEC Form 4
Chief Technology Officer
Avg Cost/Share
$5.51
Shares
6,944
Total Value
$38,229.50
Owned After
197,456
SEC Form 4
President
Avg Cost/Share
$5.38
Shares
422
Total Value
$2,270.49
Owned After
680,489
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$5.38
Shares
774
Total Value
$4,163.73
Owned After
310,684
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$4.95
Shares
5,000
Total Value
$24,752.00
Owned After
240,780
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Camblong Jurgi | SOPH | Executive Chairman | Jun 30, 2026 | Sell | $6.16 | 65,269 | $398,632.27 | 3,601,143 | |
| Camblong Jurgi | SOPH | Executive Chairman | Jun 29, 2026 | Sell | $5.93 | 18,410 | $108,058.02 | 3,601,143 | |
| Camblong Jurgi | SOPH | Chief Executive Officer | Jun 26, 2026 | Sell | $5.78 | 50,069 | $290,329.01 | 3,601,143 | |
| Camblong Jurgi | SOPH | Chief Executive Officer | Jun 25, 2026 | Sell | $5.70 | 1,373 | $7,826.10 | 3,601,143 | |
| Menu Philippe | SOPH | Chief Medical Officer | Jun 25, 2026 | Sell | $5.50 | 5,000 | $27,524.50 | 240,780 | |
| Verma Abhimanyu | SOPH | Chief Technology Officer | Jun 25, 2026 | Sell | $5.51 | 6,944 | $38,229.50 | 197,456 | |
| Muken Ross | SOPH | President | Jun 22, 2026 | Sell | $5.38 | 422 | $2,270.49 | 680,489 | |
| CARDOZA GEORGE | SOPH | Chief Financial Officer | Jun 22, 2026 | Sell | $5.38 | 774 | $4,163.73 | 310,684 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | Jun 15, 2026 | Sell | $5.01 | 4,000 | $20,056.40 | 622,280 | |
| Menu Philippe | SOPH | Chief Medical Officer | Jun 12, 2026 | Sell | $4.95 | 5,000 | $24,752.00 | 240,780 |
Compare SOPH vs Leading Stocks
See how SOPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SOPH SOPHiA GENETICS SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.